Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming ...

LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) continues to enroll its HARMONIC trial for LP-300 ...

Details for the poster presentation: Title: TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metasttic non-small cell cancer receiving eftilagimod alfa (MHC class II ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.

--(BUSINESS WIRE)--Aptar Pharma, leader in respiratory drug delivery solutions ... An integrated Poster & Exhibition session will run throughout the 3-day conference, ensuring ample opportunity ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...

He also keeps a stash of naloxone, the lifesaving opioid overdose reversal drug, and a yellow poster Puerta carried while marching ... and the other families have argued that Snapchat’s design ...